Precision Oncology Resources: Webinars

The rapid pace of innovation in oncology demands continuous learning and adaptation from cancer experts. From identifying new biomarkers to advancements in liquid biopsy technologies and evolving international standards, the challenge of staying informed is more pressing than ever.

In recognition of World Cancer Day, an expert panel will discuss early detection for intervention and monitoring after intervention. This session will explore the latest breakthroughs in cancer research, diagnostic methods, and translational science, providing guidance for enhancing patient outcomes.

Our expert panel will feature Lucia Cavelier, PhD, clinical laboratory geneticist at Karolinska University Hospital and co-director of clinical genomics at SciLifeLab, Holli M. Drendel, PhD, senior director, Molecular Pathology Laboratory and co-director, Parke Cytogenetics Laboratory at the Atrium Health Core Laboratory and Sridurga Mithraprabhu, PhD, senior research fellow at Myeloma Research Group.

Key topics:

• Recent breakthroughs: Methods for identifying early-stage cancer biomarkers.
• Liquid biopsy advances: Challenges and innovations in using blood, saliva, and urine for biomarker detection.
• Emerging tools in early detection: Exploring the role of circulating tumor DNA (ctDNA), exosomes, and microRNA.
• From research to practice: How new discoveries and technologies are shaping diagnostic strategies and patient monitoring.

Attendees will gain:

• Practical tips and expert insights into decoding cancer through the latest technologies.
• An understanding of the translational research shaping early detection and intervention strategies.
• Interactive engagement with leading cancer experts during a dedicated Q&A session.

Treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by targeted therapies, especially BTK inhibitors (BTKi), which block signaling of the B cell receptor, depriving leukemia cells of survival signals. BTKi have significantly improved the survival of CLL patients and are now a preferred standard therapy for CLL.

This webinar will highlight a study that set out to compare the effect of three different BTK inhibitors: ibrutinib, acalabrutinib, and zanubrutinib. Patient samples were obtained before and at various timepoints after treatment to identify biomarkers that could be informative of the treatment’s effect and potential side effects. In the study, a new method from Olink enabled the identification of numerous proteins, including those differing between the studied compounds.

This presentation will share the first data to characterize the effects of the different BTKi on plasma biomarker levels and will be followed by an introduction to the new Olink NGS-based proteomics kit.

Presenters:

C. I. Edvard Smith, Professor, Department of Laboratory Medicine at the Karolinska Institute

Kerhan Woo, Product Manager, Olink Proteomics

In this webinar, attendees will hear from a panel of experts in the pharmacogenomics (PGx) space. These thought leaders will discuss consensus recommendations for standardization of alleles for pharmacogenomic genotyping assays. Attendees will gain insights into these evidence-based guidelines and the implementation of standardized PGx testing within the laboratory. This panel discussion will provide insights into the trajectory of PGx utilization, including challenges, future considerations, and the potential benefits to healthcare.

Registration is open for Multiomics in Precision Medicine 2025! 

This event, developed in partnership with the University of Pennsylvania Institute for Biomedical Informatics, will explore how multiomics methods are advancing precision medicine in a range of human disease areas.

Keynotes

• Muzz Haniffa: Biological Network Co-Coordinator, Human Cell Atlas
• Marinka Zitnik: Assistant Professor, Dept of Biomedical Informatics, Harvard 
• Maya Ghoussaini: Executive Director, Computational Genomics and Application Development, Regeneron Genetics Center

This event, part of the Precision Medicine Leaders’ Summit conference series and developed in partnership with the University of Pennsylvania Institute for Biomedical Informatics, took place June 25 - 26, 2024

The conference explored how multiomics methods are advancing precision medicine in a range of human disease areas.

Recent advances in multiomic approaches — including genomics, transcriptomics, epigenomics, proteomics, and metabolomics — enable a more comprehensive picture of disease biology. This promises to accelerate the development of precision medicine, but also presents challenges for researchers, clinicians, and health systems struggling to integrate disparate data sources into a cohesive clinical strategy.

Multiomics in Precision Medicine 2024 highlighted best practices, trends, and strategies from experts who are successfully implementing a range of omics approaches to advance molecularly informed medicine.

Further details coming soon!